Université Paris Diderot, Sorbonne Paris Cité.
Blood. 2013 Sep 19;122(12):2008-10. doi: 10.1182/blood-2013-06-505115. Epub 2013 Jul 26.
Rarely in the field of cancer treatment did we experience as many surprises as with acute promyelocytic leukemia (APL). Yet, the latest clinical trial reported by Lo-Coco et al in the New England Journal of Medicine is a practice-changing study, as it reports a very favorable outcome of virtually all enrolled low-intermediate risk patients with APL without any DNA-damaging chemotherapy. Although predicted from previous small pilot studies, these elegant and stringently controlled results open a new era in leukemia therapy.
在癌症治疗领域，我们很少像急性早幼粒细胞白血病 (APL) 那样经历如此多的惊喜。然而，Lo-Coco 等人在《新英格兰医学杂志》上报告的最新临床试验是一项改变实践的研究，因为它报告了几乎所有入组的低中危 APL 患者都取得了非常有利的结果，而无需任何 DNA 损伤化疗。尽管这些结果来自之前的小型试点研究，但这些优雅且严格控制的结果开辟了白血病治疗的新时代。
